Friday, July 17, 2026
RSS

Pharmaceutical

Personalis Draws Merck's Takeover Interest: Implications for the Genomics Sector

Merck's interest in Personalis could signal new waves in the genomics market, stirring M&A speculations.

By Marcus Rivera • July 17, 2026
Pharmaceutical

Sanofi's Sarclisa Escena: Innovating Cancer Treatment Delivery

Sanofi's FDA-approved Sarclisa Escena marks a breakthrough in cancer treatment with its innovative delivery system.

Sarah Chen • Jul 17
Pharmaceutical

Merck's Lipfendra: A Game Changer in Cholesterol Treatment

Merck's Lipfendra gains FDA approval, positioning the company for significant growth in cholesterol treatment.

James McAllister • Jul 17
Trade with the conviction of the 1%.

Institutional-grade market intelligence delivered before the opening bell.

By subscribing, I agree to receive marketing emails and alerts. View our Privacy Policy. You may unsubscribe at any time.

More Stories
Markets & Money

US Import Prices Surprise Higher: What It Means for Inflation

June import prices in the US rose 0.3%, defying expectations, highlighting persistent inflation pressures.

Catherine Walsh • Jul 17, 2026
Markets & Money

Surge in US Housing Starts: A Promising Indicator for the Economy

US housing starts jumped 19% in June, signaling a robust economic outlook and potential shifts in Federal Reserve policy…

Tyler Brooks • Jul 17, 2026
Markets & Money

Fifth Third Bancorp: Positive Q2 Results Driven by Comerica Acquisition

Fifth Third Bancorp sees a boost in Q2 results following its acquisition of Comerica, indicating potential shifts in the…

Diana Kowalski • Jul 17, 2026
Pharmaceutical

BriaCell's Immunotherapy Advances: A Beacon for Canadian Biotech Investors

BriaCell Therapeutics is making waves in the biotech sector with its promising immunotherapy pipeline, drawing attention…

Marcus Rivera • Jul 17, 2026
Pharmaceutical

Speculative M&A: Merck's Interest in Personalis and Its Implications

Merck's potential takeover of Personalis could reshape oncology diagnostics, reflecting active M&A trends in biotech.

Sarah Chen • Jul 17, 2026
Energy

General Fusion's Market Debut: A New Era for Canadian Clean Energy

General Fusion's debut on the TSX Venture marks a significant milestone for the Canadian clean energy sector.

Marcus Rivera • Jul 13, 2026
Pharmaceutical

Merck's Keytruda Approval: Fueling Investor Optimism and Analyst Upgrades

Merck's recent FDA approval for Keytruda is boosting investor sentiment and leading to analyst upgrades.

Sarah Chen • Jul 13, 2026
Pharmaceutical

Q32 Bio's 60% Surge: A Game Changer for Alopecia Areata Treatment

Q32 Bio's shares jumped 60% after promising trial results for alopecia areata treatment, with Oppenheimer raising its pr…

James McAllister • Jul 13, 2026
Markets & Money

First Hawaiian Bank's Acquisition of TriCo Bancshares: A Strategic Expansion

First Hawaiian Bank's acquisition of TriCo Bancshares positions it as a leader in the Pacific banking market, promising …

Catherine Walsh • Jul 13, 2026